Values First Advisors Inc. trimmed its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 22.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,865 shares of the specialty pharmaceutical company’s stock after selling 9,642 shares during the period. […]
Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) have earned an average recommendation of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target […]
Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $32.81, but opened at $34.50. Collegium Pharmaceutical shares last traded at $33.46, with a volume of 52,196 shares. Analysts Set New Price Targets Several equities research analysts have issued reports on COLL […]
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday. Several other research firms also recently commented on COLL. Truist Financial boosted their price target on shares of Collegium Pharmaceutical from $31.00 to $37.00 and gave […]
Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $32.81, but opened at $34.50. Collegium Pharmaceutical shares last traded at $33.46, with a volume of 52,196 shares changing hands. Analyst Ratings Changes Several equities analysts have commented on COLL […]